Medicxi Ventures Management (Jersey) Ltd has filed a Form 13F-HR with the U.S. Securities and Exchange Commission, disclosing its equity securities portfolio as of the close of business on September 30, 2026.
The filing lists Giles Johnstone-Scott as the authorized signatory for the report, dated February 11, 2026. The filing identifies two primary holdings within the portfolio:
- Aura Biosciences Inc. Common Stock: The firm holds 3,039,892 shares, representing 100% of the total outstanding shares held.
- NewAmsterdam Pharma Company B.V. Ordinary Shares: The firm holds 2,182,339 shares, representing 100% of the total outstanding shares held.
Additionally, the filing reports a position in Phathom Pharmaceuticals Inc. Common Stock, with an ownership of 7,464,572 shares.
